Novus Biologicals products are now on

Recombinant Human Flt-3 Ligand/FLT3L Protein, CF


There are currently no images for Flt-3 Ligand/FLT3L (308-FK/CF).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Reactivity HuSpecies Glossary
Applications Bioactivity

Order Details

Recombinant Human Flt-3 Ligand/FLT3L Protein, CF Summary

Details of Functionality
Measured in a cell proliferation assay using BaF3 mouse pro‑B cells transfected with mouse Flt-3. The ED50 for this effect is 0.2-1 ng/mL.
Spodoptera frugiperda, Sf 21 (baculovirus)-derived human Flt-3 Ligand/FLT3L protein
Accession #
N-terminal Sequence
Protein/Peptide Type
Recombinant Proteins
>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.10 EU per 1 μg of the protein by the LAL method.


  • Bioactivity
Theoretical MW
17.5 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
17-30 kDa, reducing conditions
Read Publications using
308-FK/CF in the following applications:

Packaging, Storage & Formulations

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA.
>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute 5 µg vials at 50 µg/mL in sterile PBS. Reconstitute 25 µg or larger vials at 100 µg/mL in sterile PBS.


This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Flt-3 Ligand/FLT3L Protein, CF

  • FL
  • FLG3L
  • Flt3 ligand
  • Flt-3 Ligand
  • Flt3L
  • FLT3LG
  • fms-related tyrosine kinase 3 ligand
  • SL cytokine


Flt‑3 Ligand, also known as FLT3L, is an alpha-helical cytokine that promotes the differentiation of multiple hematopoietic cell lineages (1-3). Mature human Flt‑3 Ligand consists of a 158 amino acid (aa) extracellular domain (ECD) with a cytokine-like domain and a juxtamembrane tether region, a 21 aa transmembrane segment, and a 30 aa cytoplasmic tail (4-7). Within the ECD, human Flt‑3 Ligand shares 71% and 65% aa sequence identity with mouse and rat Flt‑3 Ligand, respectively (4-6). The human and mouse Flt‑3 Ligand proteins show cross-species activity. Flt-3 Ligand is also structurally related to M-CSF and SCF. Flt-3 Ligand is widely expressed in various human and mouse tissues. It is expressed as a noncovalently-linked dimer by T cells and bone marrow and thymic fibroblasts (1, 8). Each 36 kDa chain of the Flt-3 Ligand dimer carries approximately 12 kDa of N- and O-linked carbohydrates (8). Alternate splicing and proteolytic cleavage of the transmembrane form of the Flt-3 Ligand protein can generate a soluble 30 kDa fragment that includes the cytokine-like domain (4, 8). Alternate splicing of human Flt‑3 Ligand also generates membrane-associated isoforms that contain either a truncated cytoplasmic tail or an 85 aa substitution following the cytokine-like domain in the ECD of the Flt-3 Ligand protein (4, 5, 8). Both transmembrane and soluble forms of Flt‑3 Ligand signal through the tyrosine kinase receptor Flt-3/Flk-2 (3, 4, 6, 7). Flt‑3 Ligand induces the expansion of monocytes and immature dendritic cells as well as early B cell lineage differentiation (2, 9). Additionally, Flt-3 Ligand synergizes with IL-3, GM-CSF, and SCF to promote the mobilization and myeloid differentiation of hematopoietic stem cells (4-6). Flt-3 Ligand also cooperates with IL-2, IL-6, IL-7, and IL-15 to induce NK cell development and with IL-3, IL-7, and IL-11 to induce terminal B cell maturation (1, 10). Animal studies show that Flt‑3 Ligand reduces the severity of experimentally induced allergic inflammation (11).
  1. Wodnar-Filipowicz, A. (2003) News Physiol. Sci. 18:247.
  2. Dong, J. et al. (2002) Cancer Biol. Ther. 1:486.
  3. Gilliland, D.G. and J.D. Griffin (2002) Blood 100:1532.
  4. Hannum, C. et al. (1994) Nature 368:643.
  5. Lyman, S.D. et al. (1994) Blood 83:2795.
  6. Lyman, S.D. et al. (1993) Cell 75:1157.
  7. Savvides, S.N. et al. (2000) Nat. Struct. Biol. 7:486.
  8. McClanahan, T. et al. (1996) Blood 88:3371.
  9. Diener, K.R. et al. (2008) Exp. Hematol. 36:51.
  10. Farag, S.S. and M.A. Caligiuri (2006) Blood Rev. 20:123.
  11. Edwan, J.H. et al. (2004) J. Immunol. 172:5016.

Customers Who Viewed This Item Also Viewed...

Species: Hu
Applications: BA
Species: Hu
Applications: CyTOF-ready, Flow
Species: Hu
Applications: BA
Species: Hu
Applications: BA
Species: Rt
Applications: IHC, WB
Species: Hu, Mu, Rt
Applications: ICC/IF, IHC, IHC-P, PEP-ELISA, WB
Species: Hu
Applications: BA
Species: Hu
Applications: BA
Species: Hu
Applications: IHC, IHC-P, WB
Species: Hu
Applications: BA
Species: Hu
Applications: BA
Species: Hu
Applications: CyTOF-ready, ELISA, Flow, ICC/IF, IHC, IHC-P, PA, WB
Species: Hu, Mu
Applications: Flow-IC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
Species: Mu
Applications: ELISA(Cap), ELISA(Det), ELISA(Sta), Neut, WB
Species: Hu
Applications: BA
Species: Mu
Applications: ELISA
Species: Mu
Applications: ELISA(Cap), ELISA(Det), ELISA(Sta), Neut, WB
Species: Mu, Rt
Applications: Cell Depl, CyTOF-ready, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, InhibTFunc
Species: Hu
Applications: Bioactivity

Publications for Flt-3 Ligand/FLT3L (308-FK/CF)(62)

We have publications tested in 6 confirmed species: Human, Mouse, Primate - Callitrix jacchus (Common Marmoset), Primate - Macaca fascicularis (Crab-eating Monkey or Cynomolgus Macaque), Primate - Macaca mulatta (Rhesus Macaque), Primate - Papio anubis (Olive Baboon).

We have publications tested in 2 applications: Bioassay, Cell Culture.

Filter By Application
Cell Culture
All Applications
Filter By Species
Primate - Callitrix jacchus (Common Marmoset)
Primate - Macaca fascicularis (Crab-eating Monkey or Cynomolgus Macaque)
Primate - Macaca mulatta (Rhesus Macaque)
Primate - Papio anubis (Olive Baboon)
All Species
Showing Publications 1 - 10 of 62. Show All 62 Publications.
Publications using 308-FK/CF Applications Species
S Li, CS Wang, A Montel-Hag, HC Chen, S Lopez, O Zhou, K Dai, S Tsai, W Satyadi, C Botero, C Wong, D Casero, GM Crooks, CS Seet Strength of CAR signaling determines T�cell versus ILC differentiation from pluripotent stem cells Cell Reports, 2023-03-11;42(3):112241. 2023-03-11 [PMID: 36906850] (Bioassay, Human) Bioassay Human
Kunitomi A, Hirohata R, Arreola V, Osawa M, Kato T, Nomura M, Kawaguchi J, Hara H, Kusano K, Takashima Y, Takahashi K, Fukuda K, Takasu N, Yamanaka S Improved Sendai viral system for reprogramming to naive pluripotency. Cell Rep Methods, 2022-10-17;2(11):100317. 2022-10-17 [PMID: 36447645] (Bioassay, Human) Bioassay Human
YS Michaels, JM Edgar, MC Major, EL Castle, C Zimmerman, T Yin, A Hagner, C Lau, HH Hsu, MI Ibañez-Rio, LJ Durland, DJHF Knapp, PW Zandstra DLL4 and VCAM1 enhance the emergence of T cell-competent hematopoietic progenitors from human pluripotent stem cells Science Advances, 2022-08-24;8(34):eabn5522. 2022-08-24 [PMID: 36001668] (Bioassay, Human) Bioassay Human
R Jing, I Scarfo, MA Najia, E Lummertz d, A Han, M Sanborn, T Bingham, C Kubaczka, DK Jha, M Falchetti, TM Schlaeger, TE North, MV Maus, GQ Daley EZH1 repression generates mature iPSC-derived CAR T�cells with enhanced antitumor activity Cell Stem Cell, 2022-08-04;29(8):1181-1196.e6. 2022-08-04 [PMID: 35931029] (Bioassay, Human) Bioassay Human
SS Sahoo, VB Pastor, C Goodings, RK Voss, EJ Kozyra, A Szvetnik, P Noellke, M Dworzak, J Starý, F Locatelli, R Masetti, M Schmugge, B De Moerloo, A Catala, K Kállay, D Turkiewicz, H Hasle, J Buechner, K Jahnukaine, M Ussowicz, S Polychrono, OP Smith, O Fabri, S Barzilai, V de Haas, I Baumann, S Schwarz-Fu, European W, MR Niewisch, MG Sauer, B Burkhardt, P Lang, P Bader, R Beier, I Müller, MH Albert, R Meisel, A Schulz, G Cario, PK Panda, J Wehrle, S Hirabayash, M Derecka, R Durruthy-D, G Göhring, A Yoshimi-No, M Ku, D Lebrecht, M Erlacher, C Flotho, B Strahm, CM Niemeyer, MW Wlodarski Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes Nature Medicine, 2021-10-07;27(10):1806-1817. 2021-10-07 [PMID: 34621053] (Bioassay, Human) Bioassay Human
GA Newby, JS Yen, KJ Woodard, T Mayuranath, CR Lazzarotto, Y Li, H Sheppard-T, SN Porter, Y Yao, K Mayberry, KA Everette, Y Jang, CJ Podracky, E Thaman, C Lechauve, A Sharma, JM Henderson, MF Richter, KT Zhao, SM Miller, T Wang, LW Koblan, AP McCaffrey, JF Tisdale, TA Kalfa, SM Pruett-Mil, SQ Tsai, MJ Weiss, DR Liu Base editing of haematopoietic stem cells rescues sickle cell disease in mice Nature, 2021-06-02;0(0):. 2021-06-02 [PMID: 34079130] (Bioassay, Human) Bioassay Human
JC Reid, D Golubeva, AL Boyd, CG Hollands, C Henly, L Orlando, A Leber, J Hébert, F Morabito, G Cutrona, L Agnelli, M Gentile, M Ferrarini, A Neri, B Leber, M Bhatia Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients Cell Reports, 2021-03-16;34(11):108845. 2021-03-16 [PMID: 33730576] (Bioassay, Human) Bioassay Human
T Wang, AR Pine, AG Kotini, H Yuan, L Zamparo, DT Starczynow, C Leslie, EP Papapetrou Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets Cell Stem Cell, 2021-02-10;0(0):. 2021-02-10 [PMID: 33571445] (Bioassay, Human) Bioassay Human
S Nagel, C Pommerenke, C Meyer, RAF MacLeod, HG Drexler Aberrant expression of NKL homeobox genes HMX2 and HMX3 interferes with cell differentiation in acute myeloid leukemia PLoS ONE, 2020-10-13;15(10):e0240120. 2020-10-13 [PMID: 33048949] (Cell Culture, Human) Cell Culture Human
J Wesely, AG Kotini, F Izzo, H Luo, H Yuan, J Sun, M Georgomano, A Zviran, AG Deslaurier, N Dusaj, SD Nimer, C Leslie, DA Landau, MG Kharas, EP Papapetrou Acute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem Cells Cell Rep, 2020-06-02;31(9):107688. 2020-06-02 [PMID: 32492433] (Human) Human
Show All 62 Publications.

Reviews for Flt-3 Ligand/FLT3L (308-FK/CF) (0)

There are no reviews for Flt-3 Ligand/FLT3L (308-FK/CF). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for Flt-3 Ligand/FLT3L (308-FK/CF) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Additional Flt-3 Ligand/FLT3L Products

Blogs on Flt-3 Ligand/FLT3L

There are no specific blogs for Flt-3 Ligand/FLT3L, but you can read our latest blog posts.

Customers Who Bought This Also Bought

Contact Information

Product PDFs


Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.


Review this Product

Be the first to review our Recombinant Human Flt-3 Ligand/FLT3L Protein, CF and receive a gift card or discount.


Gene Symbol FLT3LG